Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in alzheimer's disease.
- Mechanism
- Curator reviewed
Propentofylline is a xanthine derivative and phosphodiesterase inhibitor with purported neuroprotective effects. It inhibits both phosphodiesterase and adenosine uptake. Phosphodiesterase has shown to associated with age-related memory impairment and Alzheimer's disease. β-Amyloid protein 1–42 (β42) can induce apoptosis in the cultured hippocampal neurons, suggesting that it plays an important role in causing neurodegeneration in Alzheimer's disease. Propentofylline is also capable of activating a cAMP–PKA system, depressing the caspase cascade and modifying Bcl-2 family proteins. Propentofylline blocked both the apoptotic features induced by β42 and further induced an anti-apoptotic protein, Bcl-2. It suggests that the protection of propentofylline on the β42-induced neurotoxicity is caused by enhancing anti-apoptotic action through cAMP–PKA system.
- Primary indication
- Investigated for use/treatment in alzheimer's disease.Curator reviewed
- Formula / weight
- C15H22N4O3 · 306.3602 g/mol (avg)
- Code names
- HWA-285
Resolves to
RBQOQRRFDPXAGN-UHFFFAOYSA-NSMILESCCCN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2CWhat you can answer from here — as of March 06, 2025
Which drugs share a target with Propentofylline, and which of those have an active Phase 3 trial?